Bli medlem
Bli medlem

Du är här

2022-06-29

Dicot AB (publ): Dicot demonstrates good results in new efficacy study

Press release: Uppsala, June 29, 2022. Dicot AB is developing a new potency drug aiming at becoming the first choice of treatment. The company announces today that the newly developed oral formulation demonstrates good results in a recently conducted efficacy study.

An efficacy study conducted by the company's partner, the French research company Pelvipharm, in a validated animal model for erectile function, shows good results with the new oral formulation. The effect was shown on all studied parameters in the animals measured seven days after the last dose, and the effect is statistically significant. How much longer time the effect remains and the effective dose range, remains to be evaluated.

In April, the company chose to prioritize the development of an oral formulation before starting clinical trials in humans. Prior to that, Dicot used a subcutaneous formulation for its drug candidate, that is, administration by injection under the skin. With an oral drug candidate, the market value of LIB-01 is optimized.

"This is the result of a focused development work ahead of the clinical trials on humans, planned to start mid-2023. It is very gratifying that we now have an oral formulation to work with, aiming at developing a drug with a long-term effect. We want to drastically change the conditions for treating erection problems and give affected men and couples a better quality of life.", says Elin Trampe, CEO of Dicot.

For further information, please contact:

Elin Trampe, CEO
Tel: +46 739 80 14 08
Email: elin.trampe@dicot.se

This information is such information that Dicot AB (publ) is obliged to publish in accordance with the EU Market Abuse Regulation (MAR). The information was submitted, through the agency of the above contact person, for publication on June 29, 2022.

About Dicot AB

Dicot is developing the drug candidate LIB-01, which will be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to those on the market. Research and development are conducted under own auspices up to phase 2 studies. Thereafter, Dicot's intention is to form strategic alliances, or alternatively carry out a trade sale, with larger, established pharmaceutical companies to be able to introduce LIB-01 on the world market.

Dicot is listed on Spotlight Stock Market and has approximately 3,300 shareholders. For more information, please visit www.dicot.se.

Författare Cision